Back to top
more

AstraZeneca (AZN)

(Delayed Data from NSDQ)

$77.35 USD

77.35
3,319,830

+0.48 (0.62%)

Updated Oct 11, 2024 04:00 PM ET

After-Market: $77.36 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 26% (66 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Merck (MRK) Stock Up So Far This Year on Keytruda Strength

Merck's shares are up 8.4% this year driven by strong performance and positive regulatory updates related to its PD-1 inhibitor, Keytruda.

    Novo Nordisk's (NVO) Oral Ozempic Positive in Diabetes Study

    Novo Nordisk (NVO) announces positive headline results of two phase III studies PIONEER oral formulation of Ozempic (semaglutide) as a treatment for adults with type II diabetes.

      Valeant Down as FDA Refuses to Approve Duobrii For Psoriasis

      Valeant (VRX) suffers a setback as the FDA issues a CRL for its plaque psoriasis lotion, Duobrii.

        Myriad Genetics Wins FDA SPMA Nod for BRACAnalysis CDx

        The FDA accepts Myriad Genetics' (MYGN) supplementary premarket approval (sPMA) application for BRACAnalysis CDx to identify the best responders to Pfizer's PARP inhibitor, talazoparib.

          Pharma Stock Roundup: LLY/AZN Alzheimer's Drug Fails, MRK's Keytruda Wins Approvals

          Eli Lilly (LLY)/AstraZeneca (AZN) discontinue two late-stage studies on Alzheimer's disease candidate, lanabecestat. Merck's Keytruda gets FDA nod for two new indications.

            Lilly & AstraZeneca Scrap Studies on Alzheimer's Candidate

            Eli Lilly (LLY) and AstraZeneca (AZN) are discontinuing two late-stage studies on their Alzheimer's disease candidate, lanabecestat.

              Kinjel Shah headshot

              Alzheimer's Research Stumbles Again: What's the Road Ahead?

              The discontinuation of Lilly/AstraZeneca's two late-stage studies on their Alzheimer's disease candidate, lanabecestat adds to a long list of failed treatment options for this deadly brain disease.

                AstraZeneca's Tagrisso Wins EU Nod for First-Line Lung Cancer

                AstraZeneca's (AZN) Tagrisso gets an EU nod for first-line treatment of advanced or metastatic non-small cell lung cancer in patients with epidermal growth factor receptor (EGFR) mutations.

                  TESARO Collaborates With Roche to Develop Zejula Combination

                  TESARO (TSRO) collaborates with Genentech, a subsidiary of Roche, to develop Zejula in combination with an immune-oncology drug for treating ovarian cancer.

                    Indrajit Bandyopadhyay headshot

                    3 Stocks Raising Hopes in Troubled Large-Cap Pharma Industry

                    Though the large-cap pharma industry is struggling currently, there are a few stocks that are performing well.

                      Clovis' Rubraca Gets Approval in Europe for Ovarian Cancer

                      Clovis Oncology's (CLVS) PARP inhibitor, Rubraca, gets its first approval in Europe for the treatment of BRCA-mutant ovarian cancer in third- or later-line setting.

                        AstraZeneca (AZN) Stock on Growth Path This Year: Here's Why

                        AstraZeneca's (AZN) stock is up this year while the Large-Cap Pharma industry is witnessing a decline

                          Novo Nordisk's Oral Ozempic Positive in Diabetes Study

                          Novo Nordisk's (NVO) oral formulation of Ozempic acts better in lowering blood sugar levels in adults with type II diabetes than Eli Lilly's Jardiance, in the second phase IIIa study, PIONEER 2.

                            AstraZeneca's Imfinzi Improves Survival in Lung Cancer Study

                            AstraZeneca Plc. (AZN) announces positive overall survival (OS) data from an interim analysis of a phase III PACIFIC study evaluating its oncology candidate, Imfinzi.

                              Inovio Initiates Phase II Study on Pipeline Drug VGX-3100

                              Inovio (INO) begins a phase II study to evaluate the efficacy of its pipeline candidate VGX-3100 on adult men and women with human papilloma virus (HPV)-related anal dysplasia.

                                AstraZeneca's Lokelma Gains FDA Nod to Treat Hyperkalemia

                                AstraZeneca's (AZN) Lokelma secures an FDA approval for the treatment of hyperkalemia in adults.

                                  Pharma Stock Roundup: Zoetis to Buy Abaxis, NVS Gets FDA Nod for Migraine Drug

                                  Novartis' (NVS) CGRP antibody, Aimovig gains FDA approval for prevention of migraine. Zoetis (ZTS) and Lilly (LLY) announce deals to buy smaller companies.

                                    Royal Wedding In Focus

                                    Royal Wedding In Focus

                                      Mark Vickery headshot

                                      Royal Wedding Stirs Interest in U.K. Stocks

                                      We thought it might be worthwhile to take a peek at the performance of British-oriented stocks.

                                        AstraZeneca's (AZN) Q1 Earnings & Sales Miss, Stock Down

                                        AstraZeneca (AZN) misses earnings and sales estimates in the first quarter. It maintains its previously issued outlook for 2018.

                                          Is a Surprise Coming for AstraZeneca (AZN) This Earnings Season?

                                          AstraZeneca (AZN) is seeing encouraging earnings estimate revision activity as of late and carries a favorable rank, positioning the company for a likely beat this season.

                                            AstraZeneca's (AZN) Asthma Drug Fasenra Fails in COPD Study

                                            AstraZeneca's (AZN) asthma drug Fasenra (benralizumab) fails to meet the primary endpoint in a late-stage study evaluating it for a new indication - COPD.

                                              Pharma Stock Roundup: LLY to Buy Cancer Biotech, J&J, AZN, Roche Announce Updates

                                              Lilly signs deal to buy immuno-oncology biotech ARMO Biosciences for about $1.6 billion. J&J's Darzalex gains FDA approval in first-line setting.

                                                Ekta Bagri headshot

                                                Valeant (VRX) Rallies on Earnings Beat in Q1, Raises View

                                                Valeant's (VRX) first-quarter earnings topped estimates driven by growth in Bausch + Lomb/International segment and Salix businesses. The company also upped its view.

                                                  Inovio's (INO) Q1 Loss Wider than Expected, Shares Down

                                                  Inovio (INO) reports wider-than-expected loss and revenues miss estimates in the first quarter of 2018.